Electrophysiology & Arrhythmia

Survivors of heart attack, stroke and cardiac arrest are not only less likely to maintain a job following those events, but their earnings might take a significant hit even if they stay employed, researchers reported Jan. 7 in the Canadian Medical Association Journal.

AI applied to an electrocardiogram (EKG) test reliably detected asymptomatic left ventricular dysfunction (ALVD)—a precursor to heart failure—and predicted which patients were most at risk of developing the condition in the future, according to a Mayo Clinic study published in Nature Medicine.

A side-by-side comparison of electronic and analog stethoscopes suggests a digital approach to auscultation is indeed superior to its predecessors, debunking the idea that electronic models might suffer from sound cutoffs and contact artifacts that decrease their utility.

Chronic exposure to secondhand smoke in common settings like cars, homes and casinos may increase a person’s susceptibility to cardiac alternans, a precursor to ventricular arrhythmias, according to an animal study published in Environmental Health Perspectives.

With use of cardiac implantable electronic devices on the rise, experts stress device selection, prophylactic antibiotics, pre-procedural protocols and post-implementation vigilance.

Compared to drug therapy alone, catheter ablation nearly halved the risk of death and improved a range of clinical outcomes for patients with both heart failure and atrial fibrillation (AFib) in a meta-analysis.

About 1 in 6 patients with newly diagnosed atrial fibrillation (AFib) who are considered at low risk of stroke advance to a higher risk category within one year, according to a registry study published in the Jan. 1 issue of Annals of Internal Medicine.

The FDA has granted premarket approval to Cardiva Medical’s vascular closure system for use during electrophysiology procedures such as cardiac ablation and left atrial appendage closure, the company announced Dec. 18.

U.K.-based startup Cambridge Heartware has announced the launch of its company and its first product, a wearable heart monitor powered by artificial intelligence, in early 2019.

The implantable cardioverter defibrillator (ICD) market is projected to grow to $4.3 billion by 2028, with compound annual growth of 4.1 percent, according to a new report from GlobalData.

A trial designed to test the effectiveness of additional antibiotic prophylaxis before and after cardiac electronic device implantation found that such an approach did not significantly lower the rate of subsequent infections, although there was a trend in that direction.

Cardiologs co-founder and CEO Yann Fleureau was named the European Innovator of the Year by MIT Technology Review. The company offers a cloud-based artificial intelligence (AI) platform that enables the detection of 14 cardiac arrhythmias through ambulatory electrocardiogram (ECG) readings.